RAF modulators and methods of use

Abstract

Exelixis claims a series of RAF kinase inhibitors based on a 3-oxo-2,3-dihydro-1H-isoindol-1-yl core structure. Both the chemical matter and the biochemical target appear to be new for Exelixis, and many examples have IC₅₀ values < 100 nM. These compounds are claimed to have the potential to treat diseases that are associated with uncontrolled, abnormal and/or unwanted cellular activities such as cancer.

Keywords::

• A-RAF
• B-RAF
• C-RAF
• RAF-1 kinase inhibitor

Disclaimer

The author is writing in his individual capacity and not as a representative of his employer.

Patent Details

• Title RAF modulators and methods of use

• Assignee Exelixis, Inc.

• Inventors Anand NK, Blazey CM, Bowles OJ et al.

• Priority date 07/05/2004

• Filing date 25/03/2005

• Publication date 01/12/2005

• Publication no. WO2005112932